<DOC>
	<DOCNO>NCT00537537</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy add-on adefovir telbivudine non-responders telbivudine monotherapy 24 36 initial week . Antiviral efficacy assess hepatitis B virus ( HBV ) DNA non-detectability ( PCR &lt; 300 copies/ml ) week 104 CHB .</brief_summary>
	<brief_title>To Evaluate Antiviral Efficacy Telbivudine Hepatitis B Antigen Positive ( HbeAg-positive ) Compensated Chronic Hepatitis B ( CHB )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Male female , least 18 yrs age ; HBsAg positive , HBeAg positive antiHBe negative time screen ; Quantifiable serum HBV DNA level &gt; 105copies/ml ; ALT level level ; Treatment na√Øve ; Baseline liver histology case ALT level within normal limit perform within last 12 month ) indicative chronic hepatitis B change Metavir score F &gt; 2 ; Willing able comply study drug regimen study requirement ; The patient guardian willing able explore write informed consent participate study . Patient pregnant breastfeeding . Women childbearing potential must negative serum betahuman chorionic gonadotropin ( HCG ) Screening visit ; Patient childbearing potential ( men woman ) unwilling use barrier method contraception . It require barrier method contraception use ( i.e . condom spermicide diaphragm spermicide ) patient childbearing potential ( men woman ) regardless whether hormonal agent also use method contraception ; Patient co infect hepatitis C virus ( HCV ) , HIV . Patients tested antibody HCV &amp; HIV Screening assessment ; Patient medical condition require prolonged frequent use systemic acyclovir famciclovir ; Patient currently abuse alcohol illicit drug , history alcohol abuse illicit substance abuse within precede two year ; Patient medical condition require frequent prolong use systemic corticosteroid ; Patients warfarin anticoagulant 30 day prior screen expect present study ; Patient concurrent medical condition , clinician 's discretion , likely preclude compliance schedule evaluation protocol , likely confound efficacy safety observation study Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatitis B , Chronic , Hepatitis B e Antigen positive , Adults , Telbivudine , Adefovir</keyword>
</DOC>